Another sGC stimulator with promising effects in an animal model of cardiorenal failure, praliciguat (IW-1973), showed favourable trends in metabolic and hemodynamic variables in patients with type 2 diabetes (T2D) and hypertension.72,73 However, it failed to reach the primary endpoints of improved peak rate of oxygen consumption and reduction in albuminuria in Phase 2 trials for HFpEF and diabetic nephropathy, respectively.74,75. This evidence concerns the gene SGCB and type 2 diabetes mellitus.